News Related to BNT327

Related coverage linked through entity extraction aliases.

BioNTech Faces Mixed Analyst Views, FDA Fast-Track Designation, and Leadership Transition

May 26, 2026

BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.

European Biotechs Advance Next-Generation Immunotherapy Targets Beyond PD-1/PD-L1

May 01, 2026

European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.